Although gene disruption using CRISPR/Cas9 is not always effective in treating genetic cardiomyopathies due to haploinsufficiency, precise gene correction strategies using base editors and prime editors have been applied and are potentially well-suited for correcting RBM20 mutations that cause cardiomyopathy due to a mix of loss-of-function and pathogen gain-of-function [71]. The gene discussed is RBM20; the disease is cardiomyopathy.